Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial

Worth, H.; Schacher, C.; Dethlefsen, Uwe

doi:10.1186/1465-9921-10-69

Cited by 121 publications

(85 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In murine macrophages, Eucalyptus oil inhibited inducible nitric oxide synthase mRNA expression and NO production induced by lipopolysaccharide and IFN-γ [8]. Concomitant therapy of Eucalyptol reduced exacerbations and improves lung function in patients with COPD [9]. These findings support at least for some of the essential oils of Eucalyptus species used in the clinical treatment.…”

Section: Introductionsupporting

confidence: 67%

“…In accordance with this finding, our data supported the inhibition of mucus hypersecretion in COPD rats. Clinical trials have identified the benefit of concomitant therapy of cineol on improvement of lung function in patients with COPD [9]. Another placebo-controlled, double-blind trial also showed concomitant therapy using cineole improved lung function and health condition as well as to reduce dyspnea in asthma patients [27].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Protective Effect of Eucalyptus Oil Against Pulmonary Destruction and Inflammation in COPD Rats

Wang¹

2017

JDMP

View full text Add to dashboard Cite

Eucalyptus oil (EO), an essential oil isolated from Eucalyptus leaves, was examined for its effect on LPS andKlebsiella pneumoniae -induced COPD in rats. The COPD model was induced by instilling intratracheally with LPS and Klebsiella pneumoniae (K. P). The test compound, EO (30, 100 and 300 mg/kg), Prednisone Acetate (10 mg/kg) or vehicle was instilled intragastrically after three weeks exposure of LPS and K. P, lasted for 4 weeks. EO significantly reduced amounts of inflammatory cells in bronchoalveolar lavage fluid (BALF) and blood, and decreased bronchiolitis, emphysematous changes and thickness of bronchioles. It also significantly reduced the increased AB-PAS-positive goblet cells in bronchioles. Prednisone Acetate attenuated pulmonary inflammation and airway mucus hypersecretion, but no significant difference was found on emphysema. Pretreatment with EO markly reduced the production of proinflammatory cytokines TNF-α and IL-β in lung homogenate, significantly decreased the elevated malondialdehyde (MDA) level and and increased superoxide dismutase (SOD) activity. These findings indicate that EO could exert an protective effect against LPS plus K. P-induced lung indury via inhibition of proinflammatory cytokines production and improvement of anti-oxidant status. Our results provide evidence that EO might have its potential to be a proper candidate drug in the treatment of COPD.

show abstract

Section: Introductionsupporting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Protective Effect of Eucalyptus Oil Against Pulmonary Destruction and Inflammation in COPD Rats

Wang¹

2017

JDMP

View full text Add to dashboard Cite

show abstract

“…Cineol konnte in einer placebokontrollierten COPD-Studie, in der es als Langzeittherapie zusätzlich zur medikamentösen Standardtherapie verabreicht wurde, die Exazerbationsrate im Vergleich zu Placebo signifikant senken [23].…”

Section: Pharmacotherapy Of Copdunclassified

Für jeden Schweregrad die richtige Pharmakotherapie

Pietrzak

2011

MMW - Fortschritte der Medizin

View full text Add to dashboard Cite

“…(27) Likewise, Hodder et al (28) found that the LAMA-IC and LABA-IC combinations were superior to placebo in terms of improving pulmonary function (FEV 1 and FVC) during a six-month study involving patients with moderate or severe COPD, as determined by the GOLD classification. The effects that a mucolytic agent (29) and an antioxidant (N-acetylcysteine) (30) have on pulmonary function have been shown to be similar to that of placebo. The effect of PDE4 inhibitors on pulmonary function was shown to be superior to that of placebo.…”

Section: Pulmonary Functionmentioning

confidence: 99%

Tratamento farmacológico da DPOC

et al. 2011

View full text Add to dashboard Cite

ResumoAproximadamente sete milhões de brasileiros acima de 40 anos são acometidos pela DPOC. Nos últimos anos, importantes avanços foram registrados no campo do tratamento medicamentoso dessa condição. Foi realizada uma revisão sistemática incluindo artigos originais sobre tratamento farmacológico da DPOC publicados entre 2005 e 2009, indexados em bases de dados nacionais e internacionais e escritos em inglês, espanhol ou português. Artigos com tamanho amostral menor de 100 indivíduos foram excluídos. Os desfechos sintomas, função pulmonar, qualidade de vida, exacerbações, mortalidade e efeitos adversos foram pesquisados. Os artigos foram classificados segundo o critério da Global Initiative for Chronic Obstructive Lung Disease para nível de evidência científica (grau de recomendação A, B e C). Dos 84 artigos selecionados, 40 (47,6%), 18 (21,4%) e 26 (31,0%) foram classificados com graus A, B e C, respectivamente. Das 420 análises oriundas desses artigos, 236 referiam-se à comparação de fármacos contra placebo nos diversos desfechos estudados. Dessas 236 análises, os fármacos mais frequentemente estudados foram anticolinérgicos de longa duração, a combinação β 2 -agonistas de longa duração + corticosteroides inalatórios e corticosteroides inalatórios isolados em 66, 48 e 42 análises, respectivamente. Nas mesmas análises, os desfechos função pulmonar, efeitos adversos e sintomas geraram 58, 54 e 35 análises, respectivamente. A maioria dos estudos mostrou que os medicamentos aliviaram os sintomas, melhoraram a qualidade de vida, a função pulmonar e preveniram as exacerbações. Poucos estudos contemplaram o desfecho mortalidade, e o papel do tratamento medicamentoso nesse desfecho ainda não está completamente definido. Os fármacos estudados são seguros no manejo da DPOC, com poucos efeitos adversos.Descritores: Doença pulmonar obstrutiva crônica/terapia; Doença pulmonar obstrutiva crônica/mortalidade; Revisão. AbstractApproximately seven million Brazilians over 40 years of age have COPD. In recent years, major advances have been made in the pharmacological treatment of this condition. We performed a systematic review including original articles on pharmacological treatments for COPD. We reviewed articles written in English, Spanish, or Portuguese; published between 2005 and 2009; and indexed in national and international databases. Articles with a sample size < 100 individuals were excluded. The outcome measures were symptoms, pulmonary function, quality of life, exacerbations, mortality, and adverse drug effects. Articles were classified in accordance with the Global Initiative for Chronic Obstructive Lung Disease criteria for the determination of the level of scientific evidence (grade of recommendation A, B, or C). Of the 84 articles selected, 40 (47.6%), 18 (21.4%), and 26 (31.0%) were classified as grades A, B, and C, respectively. Of the 420 analyses made in these articles, 236 were regarding the comparison between medications and placebos. Among these 236 analyses, the most commonly studied medications (in 66...

show abstract

Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial

Abstract: ISRCTN07600011.

Cited by 121 publications

References 20 publications

Protective Effect of Eucalyptus Oil Against Pulmonary Destruction and Inflammation in COPD Rats

Protective Effect of Eucalyptus Oil Against Pulmonary Destruction and Inflammation in COPD Rats

Für jeden Schweregrad die richtige Pharmakotherapie

Tratamento farmacológico da DPOC

Contact Info

Product

Resources

About